Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$142.13 USD

142.13
427,972

+1.70 (1.21%)

Updated Sep 22, 2025 04:00 PM ET

After-Market: $141.17 -0.96 (-0.68%) 4:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (92 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Neogen's (NEOG) Listeria Right Now Gets Approval from AOAC

by Zacks Equity Research

Neogen's (NEOG) Listeria Right Now likely to prove beneficial in preventing food-borne diseases in the United States.

    Zacks Equity Research

    Masimo (MASI) Scales a 52-Week High: What's Driving It?

    by Zacks Equity Research

    Masimo's (MASI) solid guidance for 2018 and a broad product spectrum drive stock.

      Zacks Equity Research

      Here's Why You Should Add Amedisys (AMED) to Your Portfolio

      by Zacks Equity Research

      Amedisys (AMED) witnesses solid Medicare and non-Medicare revenues at Home Health and Hospice divisions. A favorable demographic trend bodes well.

        Zacks Equity Research

        Becton, Dickinson Hits at a 52-Week High: What's Driving It?

        by Zacks Equity Research

        Becton, Dickinson (BDX) gains on solid fiscal Q3 results; view impressive.

          Zacks Equity Research

          AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology

          by Zacks Equity Research

          AngioDynamics' (ANGO) latest buyout to bolster its core Oncology unit; market prospects look bright.

            Zacks Equity Research

            Wright Medical Strong Overseas, Back Order Issues Persist

            by Zacks Equity Research

            Wright Medical (WMGI) rides on recent approval of AUGMENT Injectable and a solid guidance for 2018; pricing pressure prevails.

              Zacks Equity Research

              Masimo's SET Pulse Oximetry Detects Sleep Apnea in Children

              by Zacks Equity Research

              Masimo's (MASI) SET pulse oximetry successfully identifies DS in children with high risk of OSA.

                Zacks Equity Research

                Masimo (MASI) Beats on Q2 Earnings, Raises 2018 Guidance

                by Zacks Equity Research

                Masimo (MASI) gains from solid segmental performance in Q2; non-invasive technology continues to be in demand.

                  Zacks Equity Research

                  Masimo (MASI) Surpasses Q2 Earnings and Revenue Estimates

                  by Zacks Equity Research

                  Masimo (MASI) delivered earnings and revenue surprises of 1.39% and 1.74%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

                    Zacks Equity Research

                    Abiomed Gets CDSCO Nod for Impella Heart Pumps in India

                    by Zacks Equity Research

                    Abiomed's (ABMD) Impella gets regulatory approval in India; prospects in APAC look upbeat.

                      Zacks Equity Research

                      Baxter (BAX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

                      by Zacks Equity Research

                      Baxter (BAX) gains on the back of its core Renal Care segment in Q2; solid international sales encourage.

                        Zacks Equity Research

                        Stryker (SYK) Beats on Q2 Earnings, International Sales Up

                        by Zacks Equity Research

                        Stryker (SYK) gains from solid segmental performance in Q2.

                          Zacks Equity Research

                          Medidata (MDSO) Q2 Earnings Beat, Revenues Miss Estimates

                          by Zacks Equity Research

                          Medidata (MDSO) gains from solid segmental performance in Q2; banks on strategic buyouts.

                            Zacks Equity Research

                            Merit Medical (MMSI) Beats on Q2 Earnings, Raises Guidance

                            by Zacks Equity Research

                            Merit Medical (MMSI) gains from solid segmental performance in Q2; lifts 2018 guidance.

                              Zacks Equity Research

                              OPKO Health's RAYALDEE Gets Approval in Canada to Treat CKD

                              by Zacks Equity Research

                              OPKO Health's (OPK) partner VFMCRP gets regulatory nod from Health Canada to market flagship RAYALDEE; benefits patients diagnosed with chronic kidney disease.

                                Zacks Equity Research

                                Intuitive Surgical's FDA Approval for SureForm to Aid Surgery

                                by Zacks Equity Research

                                Intuitive Surgical's (ISRG) SureForm 60 stapler receives FDA approval; strengthens its profile for minimally invasive surgical solutions.

                                  Zacks Equity Research

                                  MASI or STE: Which Is a Better Investment Option Right Now?

                                  by Zacks Equity Research

                                  Masimo's (MASI) and STERIS' (STE) strong expected growth rates and impressive price performance make them close contenders in the Medical Instruments space.

                                    Zacks Equity Research

                                    Here's Why You Should Invest in Masimo (MASI) Right Now

                                    by Zacks Equity Research

                                    Masimo's (MASI) raised guidance for 2018 and strong fundamentals make it a lucrative pick.

                                      Zacks Equity Research

                                      Integer Holdings Offloads AS&O, Focuses on Cardiac Units

                                      by Zacks Equity Research

                                      Integer Holdings (ITGR) divests core AS&O unit to MedPlast, LLC for $600 million; aims to focus on cardiac business.

                                        Zacks Equity Research

                                        MOHAP Selects Masimo's (MASI) Eve for CCHD Screening in UAE

                                        by Zacks Equity Research

                                        Masimo's (MASI) Eve with Rad-97 Pulse CO-Oximeter to be integrated in nine hospitals across UAE for CCHD screening in newborns.

                                          Zacks Equity Research

                                          Masimo's (MASI) US Launch of TIR-1 to Aid Patient Monitoring

                                          by Zacks Equity Research

                                          Masimo (MASI) along with Thermomedics launches TIR-1 in the United States, market prospects look solid.

                                            Zacks Equity Research

                                            Why Is Masimo (MASI) Up 9.2% Since Its Last Earnings Report?

                                            by Zacks Equity Research

                                            Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                              Zacks Equity Research

                                              Masimo (MASI) Beats on Q1 Earnings, Raises '18 Guidance

                                              by Zacks Equity Research

                                              Masimo's (MASI) impressive growth in overseas markets drives the bottom line in Q1. New products, including NomoLine capnography and O3 organ oximetry, are major catalysts.

                                                Zacks Equity Research

                                                Medical Product Stock Earnings on May 2: CERN, ABC & More

                                                by Zacks Equity Research

                                                Given the solid prospects in the U.S. medical products industry, here we take a peek at four major Medical Product companies scheduled to report results on May 2.

                                                  Zacks Equity Research

                                                  Masimo Gets CE Mark for NomoLine, Expands in Capnography

                                                  by Zacks Equity Research

                                                  Masimo (MASI) upgrades respiratory monitoring through the newly-approved Rad-97 Pulse Co-Oximeter with integrated capnography sampling lines.